A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
SP-0336: For the motion: particle therapy: randomised trials are obligator
2015
Radiotherapy and Oncology
S166 3rd ESTRO Forum 2015 planning. After 3 months a complete response was observed in 46%, and 7% had partial response. Conclusions: Using the HYPERcollar, deep hyperthermia treatment of HNC was found to be safe, feasible, with good compliance and promising outcome. These promising early clinical results culminated in the use of hyperthermia as a standard addition to reirradiation. We will now embark on a study for (chemo-)irradiation combined with hyperthermia in primary head and neck cancer.
doi:10.1016/s0167-8140(15)40334-2
fatcat:5iigs26iq5dflb6qm7uquwurpm